Robert C. Goeltz II, Chief Financial Officer at CytomX Therapeutics, Inc. (CTMX), sold 21,517 shares at $19.60 ($426K) on 2017-03-20, disclosed to the SEC on 2017-03-21.
Open-market sale of $426k CTMX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.60 | 10,000 | $196K | 46.0% |
| 2 | $20.00 | 11,517 | $230K | 54.0% |
| Total | $19.81 avg | 21,517 | $426K | 100% |
| Filing → |
| RCUS | SELL | 2025-12-18 | $557K | — | Filing → |
| RCUS | SELL | 2025-11-26 | $125K | — | Filing → |
| RCUS | SELL | 2025-10-29 | $100K | — | Filing → |